Sun Pharma eyes to expand its footprint in specialty product segment in US

08 Oct 2015 Evaluate

Sun Pharmaceuticals is eying to expand its footprint in specialty product segment in the US. The company garnered 50% of its consolidated revenue from US market and throughout the last year it has ramped up its focus on ophthalmology and dermatology segments.

Last September Sun Pharmaceuticals also acquired exclusive rights to Merck's skin ailment drug which is under trial.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.

Sun Pharma Inds. Share Price

1729.35 8.95 (0.52%)
02-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.35
Dr. Reddys Lab 1255.45
Cipla 1510.95
Zydus Lifesciences 916.50
Lupin 2105.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×